Answers are grounded in this paper and cite their sources.
Currently, India is home to the highest number of multi-drug resistant tuberculosis (MDR-TB) patients in the world. Until now, MDR-TB was being treated with repurposed drugs which are toxic and are required to be given for up to 2 years. Two new oral anti-TB drugs, bedaquiline and delamanid have received approval in 2012 and 2014 respectively. While presenting the pharmacology, evidence of efficacy, WHO recommendations, current status of access as well as future directions regarding these two novel anti-TB agents, this paper delves into the India narrative recounting the short clinical experience thus far.
No takes yet. Share an insight, caveat, or question.
Udwadia et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: